Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression

Objective To investigate the rate of decline in forced vital capacity (FVC), and the effect of nintedanib on the rate of decline in FVC, in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD) who had risk factors for rapid decline in FVC.Methods The SENSCIS trial enrolled...

Full description

Bibliographic Details
Main Authors:	Toby M Maher, Michael Kreuter, Vanessa Smith, Yannick Allanore, Elizabeth R Volkmann, Dinesh Khanna, Christopher P Denton, Anna-Maria Hoffmann-Vold, Shervin Assassi, Masataka Kuwana, Margarida Alves, Christian Stock, Steven Sambevski
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-02-01
Series:	RMD Open
Online Access:	https://rmdopen.bmj.com/content/9/1/e002859.full

Similar Items

Effect of Nintedanib on Progression of Systemic Sclerosis‐Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial
by: Shervin Assassi, et al.
Published: (2022-10-01)

Continued nintedanib in patients with systemic sclerosis-associated interstitial lung disease: 3-year data from SENSCIS-ON
by: Yannick Allanore, et al.
Published: (2025-02-01)

Development of a multivariable prediction model for progression of systemic sclerosis-associated interstitial lung disease
by: Vanessa Smith, et al.
Published: (2024-09-01)

Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis
by: Michael Kreuter, et al.
Published: (2022-01-01)

Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases
by: Elizabeth R Volkmann, et al.
Published: (2024-12-01)

Design of ANCHOR-RA: a multi-national cross-sectional study on screening for interstitial lung disease in patients with rheumatoid arthritis
by: Jeffrey A. Sparks, et al.
Published: (2024-05-01)

Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features
by: Yannick Allanore, et al.
Published: (2019-01-01)

Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects
by: Toby M. Maher, et al.
Published: (2022-07-01)

Combining Clinical and Biological Data to Predict Progressive Pulmonary Fibrosis in Patients With Systemic Sclerosis Despite Immunomodulatory Therapy
by: Elizabeth R. Volkmann, et al.
Published: (2023-10-01)

The role of antifibrotic therapies in the treatment of systemic sclerosis–associated interstitial lung disease
by: Gonçalo Boleto, et al.
Published: (2022-01-01)

Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease.
by: Jérôme Avouac, et al.
Published: (2020-01-01)

The need for a holistic approach for SSc-ILD – achievements and ambiguity in a devastating disease
by: Anna-Maria Hoffmann-Vold, et al.
Published: (2020-07-01)

Bibliometric analysis of the pirfenidone and nintedanib in interstitial lung diseases
by: Jia Liu, et al.
Published: (2024-04-01)

Therapeutic effect of nintedanib on acute exacerbation of interstitial lung diseases
by: Yoko Ito, et al.
Published: (2019-01-01)

Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
by: Vincent Cottin, et al.
Published: (2021-03-01)

Gastrointestinal tract microbiota modifications in systemic sclerosis
by: Elizabeth R. Volkmann, et al.
Published: (2020-10-01)

Patient-level factors predictive of interstitial lung disease in rheumatoid arthritis: a systematic review
by: Michael Kreuter, et al.
Published: (2023-07-01)

Systemic Sclerosis
by: Michael Hughes, et al.
Published: (2020-07-01)

Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study
by: Marco Matucci-Cerinic, et al.
Published: (2023-02-01)

Nintedanib in chronic fibrosing interstitial lung diseases. A case series
by: Raquel García Sevila, et al.
Published: (2024-04-01)

A successful treatment of rheumatoid arthritis-related interstitial pneumonia with nintedanib
by: Tamaki Kakuwa, et al.
Published: (2019-01-01)

Nintedanib in systemic sclerosis treatment: a case report
by: Maysoun Kudsi, et al.
Published: (2024-02-01)

Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
by: Yuichiro Shirai, et al.
Published: (2021-10-01)

Nintedanib downregulates the profibrotic M2 phenotype in cultured monocyte-derived macrophages obtained from systemic sclerosis patients affected by interstitial lung disease
by: Stefano Soldano, et al.
Published: (2024-03-01)

Improvement in idiopathic interstitial pneumonia by adding macitentan to a patient unresponsive to nintedanib
by: Yosuke Tanaka, et al.
Published: (2024-01-01)

Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK
by: Giles Dixon, et al.
Published: (2024-01-01)

Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease
by: Ulrike Schmid, et al.
Published: (2021-07-01)

The role of type 1 interferon in systemic sclerosis
by: Minghua eWu, et al.
Published: (2013-09-01)

Symposium 3 <subtitle>Improving the Outcome of Systemic Sclerosis</subtitle>
by: Masataka KUWANA
Published: (2023-11-01)

Correction: Nintedanib downregulates the profibrotic M2 phenotype in cultured monocyte-derived macrophages obtained from systemic sclerosis patients affected by interstitial lung disease
by: Stefano Soldano, et al.
Published: (2024-04-01)

One‐year clinical experience on the use of Nintedanib in systemic sclerosis
by: Luca Magnani, et al.
Published: (2023-06-01)

Updates on genetics in systemic sclerosis
by: Yuko Ota, et al.
Published: (2021-06-01)

Effects of nintedanib on circulating biomarkers of idiopathic pulmonary fibrosis
by: R. Gisli Jenkins, et al.
Published: (2024-12-01)

Combination Therapy with Nintedanib and Sarilumab for the Management of Rheumatoid Arthritis Related Interstitial Lung Disease
by: Caterina Vacchi, et al.
Published: (2020-01-01)

The Role of Nintedanib in the Treatment of Progressive Pulmonary Fibrosis of Autoimmune-Related Interstitial Lung Disease
by: Aulia Rahman Ardan, et al.
Published: (2023-11-01)

Nintedanib administration after the onset of acute exacerbation of interstitial lung disease in the real world
by: Motoyasu Kato, et al.
Published: (2023-08-01)

Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres
by: Hannah Toellner, et al.
Published: (2017-11-01)

Nintedanib downregulates the transition of cultured systemic sclerosis fibrocytes into myofibroblasts and their pro-fibrotic activity
by: Maurizio Cutolo, et al.
Published: (2021-08-01)

Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials
by: Michael Kreuter, et al.
Published: (2020-01-01)

Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention
by: Fischer A, et al.
Published: (2019-12-01)